Working... Menu
Trial record 34 of 698 for:    lupus

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions (SKINDLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01597050
Recruitment Status : Completed
First Posted : May 11, 2012
Results First Posted : June 8, 2016
Last Update Posted : July 14, 2016
Information provided by (Responsible Party):
Rigel Pharmaceuticals

Brief Summary:
The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.

Condition or disease Intervention/treatment Phase
Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Drug: R932333 Drug: Placebo Phase 2

Detailed Description:
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the preliminary efficacy, safety, tolerability, and pharmacokinetics of topical R333 ointment formulated at 6% (60 mg/g) in DLE and SLE patients with active discoid lesions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cutaneous Discoid Lesions
Study Start Date : August 2012
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Arm Intervention/treatment
Active Comparator: Drug: R932333
R333 6% (60 mg/g), bid
Drug: R932333
R393233 6% (60 mg/g), bid
Other Name: R333

Placebo Comparator: Placebo
Placebo, bid
Drug: Placebo
Placebo, bid

Primary Outcome Measures :
  1. Decrease in the Total Combined Erythema and Scaling Score (Minimum of 0 and Maximum of 65) of All Treated Lesions. [ Time Frame: Up to Week 4 ]
    Percentage of patients who achieved at least a 50% decrease from baseline in the total combined Erythema and Scaling score of all treated lesions at Week 4. A decrease is an improvement in measurement of erythema and scaling of the lesions.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of SLE or DLE (DLE confirmed histologically prior to randomization).
  • At least 2 active discoid lesions secondary to SLE or DLE prior to study entry, each with a minimum Erythema Rating Score of ≥ 2. At least 1 of the active discoid lesions must have been present (by history) for ≥ 3 weeks prior to screening.
  • Patients who are taking azathioprine, hydroxychloroquine, chloroquine, quinacrine, methotrexate, and/ or oral glucocorticoids, must be receiving a stable daily dose ≥ 4 weeks prior to randomization and must remain on the same dose throughout the study. Azathioprine, hydroxychloroquine, chloroquine, quinacrine, or methotrexate must be initiated ≥ 8 weeks prior to randomization.

Exclusion Criteria:

  • Congenital or acquired immunodeficiency including: HIV infection, agammaglobulinemias, T cell deficiencies or HTLV-1 infection at any time prior to the study.
  • Lymphoproliferative disease or previous total lymphoid irradiation.
  • Uncontrolled or poorly controlled hypertension.
  • History of psoriasis, eczema, or relevant atopy.
  • Exposure to excessive or chronic UV radiation (e.g., tanning beds, sunbathing, solarium, phototherapy) within 2 weeks prior to randomization or during the study period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01597050

Layout table for location information
United States, California
Wallace Rheumatic Study Center
Los Angeles, California, United States, 90027
Stanford Dermatology
Redwood City, California, United States, 94063
United States, Indiana
Memorial Medical Group Clinical Research Institute
South Bend, Indiana, United States, 46601
United States, New York
North Shore Long Island Health System
Lake Success, New York, United States, 11042
Columbia University Medical Center
New York, New York, United States, 10032
United States, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27104
United States, Oklahoma
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
University of Pennsylvania-Dermatology Research Office
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Metroplex Clinical Research Center
Dallas, Texas, United States, 75231
University of Texas Medical School at Houston
Houston, Texas, United States, 77030
United States, Utah
University of Utah Department of Dermatology
Salt Lake City, Utah, United States, 84132
United States, Virginia
Virginia Clinical Research, Inc
Norfolk, Virginia, United States, 23507
Canada, British Columbia
University of British Columbia, Vancouver Dermatology Clinical Trials Unit
Vancouver, British Columbia, Canada, V5Z 4E8
Canada, Manitoba
Dermadvances Research
Winnipeg, Manitoba, Canada, R3C 1R4
Canada, Ontario
Lynderm Research, Inc
Markham, Ontario, Canada, L3P 1A8
Sponsors and Collaborators
Rigel Pharmaceuticals
Layout table for investigator information
Study Director: Daniel Magilavy, MD Rigel Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Rigel Pharmaceuticals Identifier: NCT01597050     History of Changes
Other Study ID Numbers: C-932333-002
First Posted: May 11, 2012    Key Record Dates
Results First Posted: June 8, 2016
Last Update Posted: July 14, 2016
Last Verified: June 2016

Keywords provided by Rigel Pharmaceuticals:
Discoid Lupus Erythematosus
Systemic Lupus Erythematosus

Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Lupus Erythematosus, Discoid
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Lupus Erythematosus, Cutaneous
Skin Diseases